CDXS
Price
$2.73
Change
+$0.21 (+8.33%)
Updated
Oct 15, 04:59 PM (EDT)
Capitalization
227.47M
15 days until earnings call
Intraday Buy/Sell Signals
MRKR
Price
$1.05
Change
-$0.01 (-0.94%)
Updated
Oct 15, 04:59 PM (EDT)
Capitalization
13.46M
Intraday Buy/Sell Signals
Interact to see
Advertisement

CDXS vs MRKR

Header iconCDXS vs MRKR Comparison
Open Charts CDXS vs MRKRBanner chart's image
Codexis
Price$2.73
Change+$0.21 (+8.33%)
Volume$6.28K
Capitalization227.47M
Marker Therapeutics
Price$1.05
Change-$0.01 (-0.94%)
Volume$400
Capitalization13.46M
CDXS vs MRKR Comparison Chart in %
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRKR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. MRKR commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Hold and MRKR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (CDXS: $2.52 vs. MRKR: $1.04)
Brand notoriety: CDXS and MRKR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 52% vs. MRKR: 26%
Market capitalization -- CDXS: $227.47M vs. MRKR: $13.46M
CDXS [@Biotechnology] is valued at $227.47M. MRKR’s [@Biotechnology] market capitalization is $13.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 1 FA rating(s) are green whileMRKR’s FA Score has 1 green FA rating(s).

  • CDXS’s FA Score: 1 green, 4 red.
  • MRKR’s FA Score: 1 green, 4 red.
According to our system of comparison, both CDXS and MRKR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while MRKR’s TA Score has 6 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 4 bearish.
  • MRKR’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, MRKR is a better buy in the short-term than CDXS.

Price Growth

CDXS (@Biotechnology) experienced а -1.56% price change this week, while MRKR (@Biotechnology) price change was -1.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was +18.38%, and the average quarterly price growth was +83.19%.

Reported Earning Dates

CDXS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDXS($227M) has a higher market cap than MRKR($13.5M). CDXS YTD gains are higher at: -47.170 vs. MRKR (-66.559). MRKR has higher annual earnings (EBITDA): -8.09M vs. CDXS (-52.78M). CDXS has more cash in the bank: 66.3M vs. MRKR (10.5M). MRKR has less debt than CDXS: MRKR (0) vs CDXS (69M). CDXS has higher revenues than MRKR: CDXS (57.2M) vs MRKR (6.59M).
CDXSMRKRCDXS / MRKR
Capitalization227M13.5M1,681%
EBITDA-52.78M-8.09M653%
Gain YTD-47.170-66.55971%
P/E RatioN/AN/A-
Revenue57.2M6.59M868%
Total Cash66.3M10.5M631%
Total Debt69M0-
FUNDAMENTALS RATINGS
CDXS vs MRKR: Fundamental Ratings
CDXS
MRKR
OUTLOOK RATING
1..100
1316
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
5865
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRKR's Valuation (14) in the Other Consumer Services industry is in the same range as CDXS (32) in the Chemicals Specialty industry. This means that MRKR’s stock grew similarly to CDXS’s over the last 12 months.

MRKR's Profit vs Risk Rating (100) in the Other Consumer Services industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that MRKR’s stock grew similarly to CDXS’s over the last 12 months.

MRKR's SMR Rating (99) in the Other Consumer Services industry is in the same range as CDXS (99) in the Chemicals Specialty industry. This means that MRKR’s stock grew similarly to CDXS’s over the last 12 months.

CDXS's Price Growth Rating (58) in the Chemicals Specialty industry is in the same range as MRKR (65) in the Other Consumer Services industry. This means that CDXS’s stock grew similarly to MRKR’s over the last 12 months.

CDXS's P/E Growth Rating (100) in the Chemicals Specialty industry is in the same range as MRKR (100) in the Other Consumer Services industry. This means that CDXS’s stock grew similarly to MRKR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSMRKR
RSI
ODDS (%)
N/A
Bullish Trend 6 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRKR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GTCDF0.02N/A
N/A
Getty Copper Inc.
PHGUF1.50N/A
N/A
Pharming Group NV
SGLOF17.82N/A
N/A
FOOD & LIFE COS LTD.
IMBBY41.31-0.30
-0.71%
Imperial Brands PLC
HMFAF6.99-0.13
-1.77%
Hammond Manufacturing Company Limited

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+0.80%
DNLI - CDXS
50%
Loosely correlated
+1.34%
PRAX - CDXS
48%
Loosely correlated
+0.34%
BEAM - CDXS
48%
Loosely correlated
+0.12%
IPSC - CDXS
47%
Loosely correlated
+1.84%
RXRX - CDXS
45%
Loosely correlated
+6.51%
More

MRKR and

Correlation & Price change

A.I.dvisor tells us that MRKR and NRIX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MRKR and NRIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRKR
1D Price
Change %
MRKR100%
+1.96%
NRIX - MRKR
33%
Poorly correlated
-5.61%
XNCR - MRKR
32%
Poorly correlated
-11.03%
MGNX - MRKR
31%
Poorly correlated
-1.22%
CDXS - MRKR
31%
Poorly correlated
+0.80%
EYPT - MRKR
30%
Poorly correlated
-1.35%
More